Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Biotech Reaches 50% Enrollment in Phase 3 ENLIGHTED Trial of Padeliporfin VTP
Details : The company's primary product candidate, WST11 (padeliporfin), is undergoing evaluation in a pivotal Phase 3 clinical trial with patients for treating low-grade upper tract urothelial carcinoma.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 27, 2024
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : EIC Accelerator
Deal Size : $14.6 million
Deal Type : Funding
ImPact Biotech Receives €13.5M Investment from European Innovation Council
Details : The funds will used to advance the company-lead product WST11 (padeliporfin). Currently, it is being evaluated in late-stage clinical trials for treating low-grade upper tract urothelial cancer.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
July 24, 2024
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : EIC Accelerator
Deal Size : $14.6 million
Deal Type : Funding
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Presents Phase 3 Results from ENLIGHTED Study of Padeliporfin in Urothelial Cancer
Details : WST11 (padeliporfin VTP) is a vascular targeted photodynamic therapy which is a minimally invasive oncology platform, it is being investigated for Low Grade Upper Tract Urothelial Cancer.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 05, 2024
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP
Details : The company's primary product candidate, WST11 (padeliporfin), is presently undergoing evaluation in a pivotal Phase 3 clinical trial with patients for low-grade upper tract urothelial carcinoma.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 24, 2024
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Biotech Presents Interim Data on Padeliporfin VTP in Urothelial Cancer
Details : The company's primary product candidate, WST11 (padeliporfin), is undergoing evaluation in a pivotal Phase 3 clinical trial with patients for treating low-grade upper tract urothelial carcinoma.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 06, 2024
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin VTP in Pancreatic Cancer
Details : ImPact Biotech is developing padeliporfin vascular targeted photodynamic (VTP) therapy, which is currently being evaluated for the treatment of patients with peripheral lung cancer.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Biotech receives FDA Orphan Drug Designation for Padeliporfin VTP in Pancreatic Cancer
Details : Padeliporfin VTP (vascular targeted photodynamic therapy) is a minimally invasive oncology platform for the treatment of solid tumors and Pancreatic Cancer and has received Fast Track designation and Orphan Drug Designation for adult patients with low-gr...
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 07, 2023
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Padeliporfin VTP (vascular targeted photodynamic therapy) is a minimally invasive oncology platform for the treatment of peripheral lung cancer and pancreatic cancer and has received Fast Track designation and Orphan Drug Designation for adult patients w...
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 08, 2023
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable